Portage Biotech Reports FY24 Net Result Of $(75.4)M Vs $(104.7)M Last Year; Says Discontinuing INKT Clinical Trial For PORT-2; Continues To Explore Strategic Alternatives, Including Restructurings (Both In And Out Of Court)
Portage Biotech Reports FY24 Net Result Of $(75.4)M Vs $(104.7)M Last Year; Says Discontinuing INKT Clinical Trial For PORT-2; Continues To Explore Strategic Alternatives, Including Restructurings (Both In And Out Of Court)
The decrease was primarily due to lower non-cash losses on impairment related to the Company's identifiable intangible assets, goodwill, and certain investments and convertible note receivable.
主要是由于公司可识别无形资产、商誉、某些投资和可转换票据应收款的非现金减值损失降低所致。
As of March 31, 2024, the Company had cash and cash equivalents of approximately $5.0 million and total current liabilities of approximately $2.9 million.
截至2024年3月31日，公司的现金及现金等价物约为$500万，总流动负债约为$290万。
"After reviewing Portage's funding requirements, which necessitated discontinuing the clinical development of its iNKT program and pausing patient enrollment in the ADPORT-601 clinical trial of PORT-6 (adenosine 2A inhibitor) and PORT-7 (adenosine 2B inhibitor), we continue to explore strategic alternatives. These may include finding a partner for one or more of our assets, a sale of our company, a merger, restructurings (both in and out of court), a company wind down, further financing efforts, or other strategic actions," said Dr. Ian Walters, Chief Executive Officer and Chairman of Portage.
波提奇医疗首席执行官兼主席伊恩·沃尔特斯博士表示：“在审查波提奇的资金需求后，我们不得不停止该公司iNKt项目的临床开发和ADPORt-601临床试验的患者入组，并继续探索战略性选择，其中可能包括寻找一些资产的合作伙伴、销售我们的公司、合并、重组（在和外出庭时）、公司解散、进一步融资或其他战略性措施。”